(R)-3-(2-amino-3-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl amino)-3-oxopropylthio)propane-1,2-diyl dipalmitate | 1610431-10-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-3-(2-amino-3-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl amino)-3-oxopropylthio)propane-1,2-diyl dipalmitate
• 英文别名: [3-[(2R)-2-amino-3-[4-[[6-amino-2-(butylamino)-8-oxo-7H-purin-9-yl]methyl]anilino]-3-oxopropyl]sulfanyl-2-hexadecanoyloxypropyl] hexadecanoate
• CAS: 1610431-10-1
• 化学式: C₅₄H₉₂N₈O₆S
• 分子量: 981.44
• InChiKey: FLPVAFAKTRVSSA-RIVVNBGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.5
• 重原子数：
  69
• 可旋转键数：
  45
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  229
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS
  申请人：CAYLA

  公开号：US20140141033A1

  公开（公告）日：2014-05-22

  A conjugated compound of formula Q-Z—R 4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R 4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  一种配方为Q-Z—R4的共轭化合物，其中Q是TLR7和/或TLR8激动剂，Z—R4是TLR2激动剂，以及它们在治疗感染、癌症或免疫紊乱或用于疫苗中的用途。
• Conjugated TLR7 and/or TLR8 and TLR2 agonists
  申请人：Invivogen

  公开号：EP2732825A1

  公开（公告）日：2014-05-21

  The present invention relates to a conjugated compound of formula Q-Z-R4 wherein Q is a TLR7 and/or TLR8 agonist and Z-R4 is a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

  本发明涉及一种式 Q-Z-R4 的共轭化合物（其中 Q 为 TLR7 和/或 TLR8 激动剂，Z-R4 为 TLR2 激动剂）及其在治疗感染、癌症或免疫紊乱或疫苗中的用途。
• SMC combination therapy for the treatment of cancer
  申请人：Children's Hospital of Eastern Ontario Research Institute Inc.

  公开号：US10441654B2

  公开（公告）日：2019-10-15

  The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

  本发明包括提高 SMC 治疗癌症疗效的方法和组合物。特别是，本发明包括用于组合疗法的方法和组合物，其中包括 SMC 和至少刺激一种或多种凋亡或免疫途径的第二种制剂。第二种药剂可以是免疫刺激化合物或溶瘤病毒等。
• SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
  申请人：Children's Hospital of Eastern Ontario Research Institute Inc.

  公开号：US20170239347A1

  公开（公告）日：2017-08-24

  The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
• Compositions and Methods for Inducing an Immune Response
  申请人：Yale University

  公开号：US20180311334A1

  公开（公告）日：2018-11-01

  The invention provides a modified cell having an immunomodulatory molecule bound to the cell surface. In some aspects, the invention provides compositions and methods for the treatment and prevention of a microbial infection and microbial infection-related diseases and disorders. The present invention also provides methods of inducing an immune response against a pathogen.